Investors
A category-defining bet on pre-emptive care.
Anthogen is building the operating system for at-home chronic disease management — and the data layer that makes it pay.
A one-minute overview of Anthogen.
The missing piece
The problem isn't diagnosis. It's adherence.
Care plans are written in the clinic. Success happens at home — out of sight of the doctor, where most patients fall off track. Anthogen is built for the gap in between.
In the clinic
A care plan is written. The patient is sent home with instructions, a referral, and a follow-up months away.
At home
Daily life takes over. Without a coach in the room, only 30% of cardiac rehab patients complete their program in traditional outpatient care.
With Anthogen
Sensor-driven feedback, real-time coaching, and AI personalization lift adherence to 89% — the difference between a billed service and a clinical outcome.
$412B
Global digital therapeutics market by 2032
133M
U.S. adults living with at least one chronic condition
6 modules
ARTA condition modules in development
Why now
A reimbursement-driven system at its limits.
Demand for healthcare from an aging population is rising sharply, just as clinicians leave the field. Anthogen reduces the burden of chronic disease by changing daily behavior — at a fraction of the cost of acute care. The result is better outcomes, lower spend, and a durable software business sitting between patient and payer.
The technology
Proprietary AI that learns each patient.
Our AI doesn't just track behavior. It learns which virtual coaching method works best for each individual — adapting in real time using sensor-driven feedback from mobile devices and wearables. Hyper-personalized engagement that drives long-term behavior change at scale.
This is not another wellness app. It's a complete chronic care management system.
Adaptive coaching engine
Selects from a library of intervention styles per session, per patient.
Sensor-driven feedback
Phone, tablet, and wearable signals flow into the model continuously.
Hyper-personalization
Tone, intensity, and timing tuned to the individual — not a cohort average.
Compounding data moat
Each session improves the model — and is impossible to retroactively assemble.
Investment thesis
Three structural tailwinds.
Reimbursement is here
CMS and major payers now reimburse remote therapeutic monitoring (CPT 98975–98981). Anthogen's modules are designed around these codes from day one.
Capital-efficient distribution
We sell to health systems and self-insured employers — channels with concentrated decision-making and recurring per-patient economics.
Defensible data moat
Each ARTA module compounds a behavioral dataset that improves personalization — and is impossible to retroactively assemble.
Milestones
From 40 patients to regional networks.
Cardiac rehabilitation pilot
First clinical pilot — 40 patients across partner sites.
CardiFit launches
Released with four cardiology practices live on the platform.
Practice expansion
Additional cardiology practices onboarded across two months.
Regional hospital networks
Expanding from individual practices into regional health-system contracts.
Traction
Real patients. Real outcomes. Real revenue.
1,000+
Patients enrolled across active CardiFit pilots.
Toward 5,000 enrollee milestone
12 / 50
Health-system partners under LOI or contract.
Series A goal: 50 systems
$4.2M
ARR run-rate as of Q1 2026.
Toward $10M ARR by year-end
89%
+197% vs baselineProgram adherence — the single metric payers care about.
- CardiFit
- 89%
- Traditional rehab
- 30%
−62%
Reduction in 30-day readmissions across pilot cohorts — the foundation of every payer ROI conversation.
The pitch
"Anthogen isn't just participating in the evolution of healthcare — we're building the infrastructure for it."
— Investor overview, 2026
The round
Series A — open through Q3 2026.
We are raising to expand CardiFit into 50 health systems, complete the JointFit and DiabFit module launches, and grow our clinical evidence base.
Round size
$22M
Lead
Confirmed — name on request
Use of funds
Commercial expansion · clinical evidence · platform
Closing
Q3 2026
FAQ
Investor questions, answered.
- What stage is Anthogen at?
- Anthogen is a commercial-stage digital therapeutics company. CardiFit is live across multiple health-system pilots with a $4.2M ARR run-rate as of Q1 2026, and we are raising a $22M Series A to scale. Request investor materials
- How does Anthogen generate revenue?
- Anthogen sells per-patient subscriptions to health systems and self-insured employers. Our modules are designed around reimbursable CPT codes (including 93798/93799 and 98975–98981), creating recurring economics with concentrated decision-makers. Request investor materials
- What is the size of the Series A round?
- We are raising $22M to expand CardiFit into 50 health systems, complete the JointFit and DiabFit module launches, and grow our clinical evidence base. The round is led and closing in Q3 2026. Request investor materials
- How can I request the data room?
- Reach the team at investors@anthogen.com or use the investor materials request form. We typically share the data room after an introductory call with leadership. Request investor materials
Want to dig deeper?
Request the data room and a meeting with the leadership team.
Request investor materials